Table 4 Tumor samples are compared against control samples at the RNA (column B), proteome (column C) and phosphoproteome (column D) levels for the 74 predicted mediators. The gene is indicated as “dysregulated”, if it is ranked at the top 5% of all genes based on P-value
From: Multi-omics data integration reveals novel drug targets in hepatocellular carcinoma
Gene | RNA all vs all, top 5% | PROT all vs all, top 5% | PHOSPHOPROTEOME all vs all, top 5% |
|---|---|---|---|
PTEN | |||
STAT3 | |||
NFKB1 | |||
TNF | |||
AKT1 | |||
IGF1R | |||
HIF1A | |||
CAMK2A | |||
ZEB2 | |||
GSK3B | dysregulated | ||
ARG1 | |||
FBXW7 | |||
RUNX1 | |||
SIRT1 | |||
ZFPM2 | |||
AKT2 | |||
VEGFA | dysregulated | ||
EGFR | |||
YAP1 | |||
ROCK1 | |||
MXI1 | |||
HDAC4 | |||
AKT3 | dysregulated | ||
DNMT1 | |||
MYC | |||
GSTM1 | |||
CCND1 | dysregulated | ||
CLIC5 | |||
PRKAA1 | |||
FLT1 | |||
GRB2 | |||
ATXN1 | |||
FOXO3 | |||
KIT | dysregulated | ||
TBX3 | |||
UCP2 | |||
TSC1 | |||
SMAD4 | |||
TIMP3 | |||
BACE1 | |||
RUNX2 | dysregulated | ||
YWHAZ | dysregulated | ||
IRS1 | |||
KLF4 | |||
EZH2 | dysregulated | ||
HELLS | |||
BCL2L11 | |||
AKT | dysregulated | ||
VCAN | |||
NF1 | |||
SRM | |||
AMD1 | |||
SEMA4B | |||
ZEB1 | |||
MEF2C | dysregulated | ||
CTGF | |||
KRAS | |||
CREB1 | |||
RIOK3 | |||
EGR1 | |||
MECP2 | |||
ENPP6 | dysregulated | ||
INPP5D | |||
ELK1 | |||
PAFAH1B1 | |||
MTOR | dysregulated | ||
NR1I3 | |||
CAB39 | |||
MEOX2 | |||
SMAD5 | |||
NRAS | |||
YY1 | |||
RAF1 | |||
CAV2 |